Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EORTC CLTF 2021 | Novel therapies on the horizon for CTCL

Pablo Ortiz Romero • 14 Oct 2021
EORTC CLTF 2021
Cutaneous T-Cell Lymphoma Lymphoma Non-Hodgkin Lymphoma Rare Diseases Antibodies ASTX660 Lacutamab Mogamulizumab
MOGAT

Pablo Ortiz Romero, MD, PhD, University Complutense, Hospital 12 de Octubre, Medical School, Institute i+12, Madrid, Spain, shares his views on the future treatment landscape for cutaneous T-cell lymphoma (CTCL), highlighting the upcoming MOGAT trial (NCT04128072) of mogamulizumab in combination with total skin electron bean therapy (TSEB) in patients with stage IB-IIB CTCL. Prof. Romero also comment on novel therapies being explored for CTCL including ASTX660 and lacutamab. This interview took place at the EORTC Cutaneous Lymphoma Group 20-21 meeting in Marseille.

More from Pablo Ortiz Romero

1:05
RESMAIN: resmonistat for CTCL maintenance
Pablo Ortiz Romero • 14 Oct 2021
0:58
Approval of brentuximab vedotin for CD30+ mycosis fungoides
Pablo Ortiz Romero • 14 Oct 2021
1:23
Pegylated liposomal doxorubicin as maintenance in mycosis fungoides
Pablo Ortiz Romero • 14 Oct 2021
0:38
Link between blood involvement and HRQoL in CTCL patients receiving mogamulizumab
Pablo Ortiz Romero • 14 Oct 2021

Related Videos

1:24
Employing CAR-T therapies in earlier lines of large B-cell lymphoma treatment
Paolo Cortesi • 24 Apr 2024
2:45
The value of axi-cel as a second-line treatment in R/R LBCL
Paolo Cortesi • 24 Apr 2024
5:42
Promising therapeutic efficacy of EBV-specific T-cell immunotherapy tabelecleucel in PTLD
Nina Worel • 25 Apr 2024
4:24
Investigating production failure and out-of-specification production of CAR T-cell therapeutics
Nina Worel • 25 Apr 2024
The content of VJHemOnc is intended for healthcare professionals